PICKING up her phone, Oonagh Van der Berg goes to read a WhatsApp message – but the 45-year-old, from Belfast, can’t focus.

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

Dec 12 (Reuters) - The European Medicines ‌Agency's ​committee on Friday ‌recommended extending the use of Eli Lilly's ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.